Clinical trials are widely accepted as the most expensive part of the medical innovation cycle and therefore likely make up a significant portion of total R&D costs. But there is no transparency around the actual costs of clinical ...
Pharmaceutical corporations’ top priority is making shareholders happy. So if a medicine, test or vaccine won’t earn big money or boost stock prices, it might not get made. No matter how badly it’s needed.
